Also known as Aldactone, Espironolactona, SC 9420, SPL, Spironolactonum, Spironolattone

A synthetic 17-spironolactone corticosteroid with potassium-sparing diuretic, antihypertensive, and antiandrogen activities.Spironolactone competitively inhibits adrenocortical hormone aldosterone activity in the distal renal tubules, myocardium, and vasculature. This agent may inhibit the pathophysiologic effects of aldosterone produced in excess by various types of malignant and benign tumors.

Originator: NCI Thesaurus | Source: The website of the National Cancer Institute (http://www.cancer.gov)

Can I take Spironolactone while breastfeeding?

Spironolactone appears acceptable to use during breastfeeding.

Drug levels

Maternal Levels. The major metabolite of spironolactone, canrenone, was measured in the serum and milk of a 17-day postpartum woman who was taking 25 mg of spironolactone four times daily. Milk canrenone levels 2 hours after the dose were 104 mcg/L, and 47 mcg/L at 14.5 hours after the dose. The authors estimated that the nursing infant would receive about 0.2% of the mother’s total daily dosage in the form of canrenone.[1] Active sulfur-containing metabolites were not measured.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in breastfed infants

Maternal Levels. The major metabolite of spironolactone, canrenone, was measured in the serum and milk of a 17-day postpartum woman who was taking 25 mg of spironolactone four times daily. Milk canrenone levels 2 hours after the dose were 104 mcg/L, and 47 mcg/L at 14.5 hours after the dose. The authors estimated that the nursing infant would receive about 0.2% of the mother’s total daily dosage in the form of canrenone.[1] Active sulfur-containing metabolites were not measured.

Infant Levels. Relevant published information was not found as of the revision date.

Possible effects on lactation

Intense diuresis can suppress lactation;[3][4] however, it is unlikely that spironolactone alone is sufficiently potent to cause this effect. Spironolactone can also cause gynecomastia.[5]

References

1. Phelps DL, Karim A. Spironolactone: relationship between concentrations of dethioacetylated metabolite in human serum and milk. J Pharm Sci. 1977;66:1203. PMID: 894512

2. Gutgesell M, Overholt E, Boyle R. Oral bretylium tosylate use during pregnancy and subsequent breastfeeding: a case report. Am J Perinatol. 1990;7:144-5. PMID: 2331276

3. Healy M. Suppressing lactation with oral diuretics. Lancet. 1961;1:1353-4.

4. Cominos DC, Van Der Walt A, Van Rooyen AJ. Suppression of postpartum lactation with furosemide. S Afr Med J. 1976;50:251-2. PMID: 3858

5. Bowman JD, Kim H, Bustamante JJ. Drug-induced gynecomastia. Pharmacotherapy. 2012;32:1123-40. PMID: 23165798

Last Revision Date

20150310

Disclaimer:Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Source: LactMed – National Library of Medicine (NLM)

3D Model of the Spironolactone molecule

MolView – data visualization platform